CAM
BIIB icon

Cormorant Asset Management’s Biogen BIIB Stock Holding History

Cormorant Asset Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-10,000
Closed -$3.06M – 55
2014
Q1 		$3.06M Buy
+10,000
New +$3.17M 0.7% 42

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Cormorant Asset Management's BIIB Position: Q2 2014 in Review

Cormorant Asset Management sold out of Biogen (BIIB) in Q2 2014, closing a stake of 10,000 shares — an estimated $3.06M sold.

Cormorant Asset Management first reported a position in BIIB in Q1 2014 and held it in 1 quarter. The position peaked at $3.06M in Q1 2014. 782 funds tracked by Wall St. Rank hold BIIB as of Q2 2014.

  • Cormorant Asset Management reported no remaining Biogen position as of Q2 2014 after selling out during the quarter.
  • Cormorant Asset Management sold 10,000 Biogen shares in Q2 2014, an estimated $3.06M.
  • Cormorant Asset Management first reported a position in Biogen in Q1 2014 and held it in 1 quarter.
  • Cormorant Asset Management's Biogen position peaked at $3.06M in Q1 2014.
  • 782 funds tracked by Wall St. Rank held Biogen as of Q2 2014.

Based on Cormorant Asset Management's 13F filing for Q2 2014, filed 14 Aug 2014.